Context Therapeutics Inc. (NASDAQ:CNTX) Given Consensus Recommendation of "Buy" by Analysts

Shares of Context Therapeutics Inc. (NASDAQ:CNTX - Get Free Report) have earned an average rating of "Buy" from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. Seven equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have issued a report on the stock in the last year is $6.17.

Several equities research analysts have recently issued reports on CNTX shares. William Blair assumed coverage on shares of Context Therapeutics in a research report on Monday. They set an "outperform" rating on the stock. Citizens Jmp upgraded Context Therapeutics to a "strong-buy" rating in a research report on Wednesday, January 8th. JMP Securities assumed coverage on Context Therapeutics in a research report on Wednesday, January 8th. They issued an "outperform" rating and a $4.00 target price on the stock. D. Boral Capital reiterated a "buy" rating and set a $9.00 target price on shares of Context Therapeutics in a research report on Wednesday, April 9th. Finally, HC Wainwright restated a "buy" rating and issued a $5.00 price target on shares of Context Therapeutics in a research report on Friday, March 21st.

Context Therapeutics Price Performance

Shares of NASDAQ:CNTX traded up $0.10 during mid-day trading on Friday, reaching $1.04. 54,140 shares of the company traded hands, compared to its average volume of 405,741. Context Therapeutics has a 52 week low of $0.55 and a 52 week high of $2.75. The firm has a market cap of $93.29 million, a PE ratio of -1.14 and a beta of 2.18. The company's 50 day moving average price is $0.77 and its 200-day moving average price is $1.22.

Context Therapeutics (NASDAQ:CNTX - Get Free Report) last announced its quarterly earnings data on Thursday, March 20th. The company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.05) by $0.01. On average, research analysts predict that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

A number of large investors have recently bought and sold shares of CNTX. State Street Corp grew its holdings in shares of Context Therapeutics by 21.5% in the third quarter. State Street Corp now owns 111,907 shares of the company's stock worth $219,000 after purchasing an additional 19,800 shares during the last quarter. Clear Harbor Asset Management LLC raised its stake in shares of Context Therapeutics by 60.6% during the fourth quarter. Clear Harbor Asset Management LLC now owns 57,804 shares of the company's stock valued at $61,000 after acquiring an additional 21,804 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Context Therapeutics in the fourth quarter valued at approximately $29,000. Citadel Advisors LLC bought a new position in Context Therapeutics in the fourth quarter worth approximately $31,000. Finally, Millennium Management LLC increased its holdings in Context Therapeutics by 24.2% during the 4th quarter. Millennium Management LLC now owns 178,718 shares of the company's stock worth $188,000 after purchasing an additional 34,835 shares during the period. Hedge funds and other institutional investors own 14.03% of the company's stock.

About Context Therapeutics

Context Therapeutics Inc, a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.